The pharmacogenetics of methotrexate in inflammatory bowel disease.

OBJECTIVES Methotrexate (MTX) is an effective immunosuppressive treatment in inflammatory bowel disease (IBD) but its use is limited by unpredictable toxicity and efficacy. MTX metabolism is complex involving a number of enzymes. An individual's response to MTX may in part be genetically determined by functional genetic variation in genes encoding these enzymes. We report a pharmacogenetic evaluation of MTX therapy in IBD. METHODS We studied 102 IBD patients treated with MTX, and 202 patients with Crohn's disease (CD), 205 patients with ulcerative colitis (UC) and 189 healthy volunteers served as controls to assess allele frequencies in the disease and healthy populations. All subjects were genotyped for four polymorphisms: G80A in the reduced folate carrier (RFC1) gene, G452T in the gamma-glutamyl hydrolase (GGH) gene and C677T and A1298C in the methylenetetrahydrofolate reductase (MTHFR) gene. Three non-conservative SNPs in the RFC1 and the MTHFR gene could not be detected in our patient cohort. Genotype-phenotype associations were evaluated with respect to efficacy and toxicity of MTX therapy. RESULTS No significant differences in the allele frequencies between CD, UC and healthy controls were detected. Overall 21% of patients experienced MTX side effects. Patients homozygous for the MTHFR 1298C allele were more likely to experience one or more side effects compared to patients with the wild-type 1298AA genotype (21.0 vs. 6.3%, P < 0.05). None of the genotyped SNPs or haplotypes, either alone or in combination, was associated with short-term efficacy or sustained response. CONCLUSIONS Side effects of MTX in IBD are associated with a SNP in the MTHFR gene but response cannot be predicted by any of the investigated SNPs.

[1]  D. Jewell,et al.  Oral methotrexate in ulcerative colitis , 2005, Alimentary pharmacology & therapeutics.

[2]  M. Lucock,et al.  Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate , 2004, Gut.

[3]  Katie Smith,et al.  Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[4]  M. Relling,et al.  A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. , 2004, Pharmacogenetics.

[5]  J. Galivan,et al.  Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. , 2003, Gene.

[6]  Y. Assaraf,et al.  Loss of folylpoly‐γ‐glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation‐dependent novel antifolates in multiple human leukemia sublines , 2003, International journal of cancer.

[7]  H. McLeod,et al.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? , 2003, Annals of the rheumatic diseases.

[8]  M. Krajinovic,et al.  Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. , 2002, Blood.

[9]  O. Paoluzi,et al.  Azathioprine or methotrexate in the treatment of patients with steroid‐dependent or steroid‐resistant ulcerative colitis: results of an open‐label study on efficacy and tolerability in inducing and maintaining remission , 2002, Alimentary pharmacology & therapeutics.

[10]  D. Jewell,et al.  The efficacy of methotrexate for maintaining remission in inflammatory bowel disease , 2002, Alimentary pharmacology & therapeutics.

[11]  A. Taniguchi,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. , 2002, Pharmacogenetics.

[12]  M. Krajinovic,et al.  Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia , 2002, The Lancet.

[13]  C. Ulrich,et al.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. , 2001, Blood.

[14]  J H Eckfeldt,et al.  The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. , 2001, Atherosclerosis.

[15]  P. Martreau.  [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.

[16]  R. Moreno-otero,et al.  6‐Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[17]  R. Modigliani,et al.  Methotrexate in Crohn's disease: long-term efficacy and toxicity , 2000, American Journal of Gastroenterology.

[18]  R. Corbally,et al.  Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications , 1999, Gut.

[19]  M. Rots,et al.  Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. , 1999, Blood.

[20]  R. Rozen,et al.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. , 1998, Molecular genetics and metabolism.

[21]  F. Gabreëls,et al.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? , 1998, American journal of human genetics.

[22]  B. Feagan.  Methotrexate treatment for Crohn's disease. , 1998, Inflammatory bowel diseases.

[23]  M. Buxton,et al.  Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study , 1996, BMJ.

[24]  A. Lavy,et al.  Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. , 1996, Gastroenterology.

[25]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[26]  G. Curt,et al.  Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.

[27]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[28]  R. Rozen,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[29]  M. Bunce,et al.  Molecular typing for the MHC with PCR-SSP. , 1999, Reviews in immunogenetics.

[30]  P. Frosst,et al.  Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. , 1996, American journal of human genetics.

[31]  M. Relling,et al.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.

[32]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[33]  H. Blom,et al.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. , 1995, American journal of human genetics.